StockData
Curanex Pharmaceuticals Inc logo

Curanex Pharmaceuticals Inc (CURX) stock

CURXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$4.63−0.17 (-3.44%)

Close on Nov 16, 2026Market cap $7.27MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026

Valuation

Market cap
$7.27M
P/E ratio
–
Price to sales
–
Price to book
2.86
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$12.33M
EPS, diluted
-$8.63
Book value per share
$1.68
Diluted shares
2M

Trading

Previous close
$4.80
Open
$4.63
Day's range
$4.63 – $4.94
Volume
4,064
Average volume (20 days)
9,201
52-week range
$3.58 – $13.33
RSI (14 days)
40.4
Volatility (1 year)
98.3%
Relative volume
0.24×

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 16, 2026. The S&P 500 is measured by the SPY fund.

PeriodCURXS&P 500DifferenceCURX per yearS&P 500 per year
1 month+0.3%-3.1%+3.4 pts
3 months+6.6%-4.5%+11.1 pts
Year to date-29.9%+9.4%−39.3 pts
1 year-54.3%+11.3%−65.6 pts

Three years at a glance

Fiscal years 2023 to 2025 and trailing twelve months, USD

Operating income

-$12.43M

Net income

-$12.33M

EPS, diluted

-$8.63
Reported periodTrailing twelve months

Press releases

Releases Curanex Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

About Curanex Pharmaceuticals

Pharmaceutical Preparations

Curanex Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing botanical medicines for patients with inflammatory diseases. The company's lead drug candidate is Phyto-N, a proprietary botanical extract derived from a medicinal plant used in traditional Chinese medicine. Curanex is advancing a development pipeline targeting six core indications: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout, with its primary development focus on ulcerative colitis.

Company profile, executives and history

Curanex Pharmaceuticals stock: common questions

What is Curanex Pharmaceuticals's stock price?

CURX closed at $4.63 on Nov 16, 2026, down 3.44% on the day. Over the past 52 weeks it traded between $3.58 and $13.33.

What is Curanex Pharmaceuticals's market cap?

Curanex Pharmaceuticals was worth $7.27M at the close on Nov 16, 2026: the share price times the diluted shares outstanding.

What is CURX's P/E ratio?

Curanex Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$8.63), so it has no meaningful P/E ratio.

Does Curanex Pharmaceuticals pay a dividend?

No. Curanex Pharmaceuticals has not paid a cash dividend over the last twelve months.

How has CURX stock performed over the past year?

Including dividends, CURX returned -54.3% over the past year, against +11.3% for the S&P 500.

Who are Curanex Pharmaceuticals's competitors?

Companies most similar to Curanex Pharmaceuticals by business, industry and size include ANL, MTRI, EVMN, MENS, EPRX.

See a number that looks wrong?